Resources
134 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2024
This article discusses strategies to recruit primary care providers who will implement a medication for opioid use disorder integrated care model. The Pennsylvania Project, Project RAMP, was guided by a framework highlighting design, recruitment, pre-implementation, and implementation processes. The study covers the implementation sites that were recruited, the planning and implementation activities, and evaluation of the processes.
Posted 5/17/2024
The resource LEVELING UP: A Guide for Optimizing the Impact of Your RCORP Consortium to Support Rural Recovery was developed by RCORP-TA and is designed to support RCORP project directors and teams in effectively structuring, leading, and managing consortia throughout the award period and beyond.
Posted 5/5/2024 (updated 5/7/2024)
The four-module implementation toolkit developed by the National Center on Substance Abuse and Child Welfare offers strategies to develop peer support specialist programs for parents affected by substance use—whose children and families are involved with child welfare.
Posted 4/12/2024
These documents from the South Southwest MHTTC provide information about Peer Specialists in crisis settings.
Posted 4/12/2024
Researchers used data from electronic license renewals in 2021 to examine what factors affect the likelihood of providing medication-assisted treatment (MAT) for opioid use disorder. Physicians and nurse practitioners who were younger, practiced in a public or community health center, and offered a sliding fee scale in their practice had a greater likelihood of providing MAT.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 6/2/2021 (updated 4/10/2024)
This webinar provided a review of basic principles of integrated behavioral health and an update on recent outcomes and implementation research.
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.